Navigation Links
Personalized Medicine - The Genomic Revolution in Cardiac Care
Date:9/19/2007

ersonalized cardiovascular care. Researchers, cardiologists, policy makers, medical industry and anyone with an interest in personalized medicine and genomics will want to attend.

"By identifying the genes that can cause and cure heart disease, researchers hold in their hands the potential for personalized medicine. Understanding research advances in the science of the human gene and its application to cardiovascular disease will make possible life saving changes in cardiac care," says Dr. Timothy McCaffrey, who is the program co-chair for the one-day symposium as well as director of the McCormick Genomics Center at The George Washington University. The McCormick Genomics Center is among the nation's innovative leaders in genomics research and application and is one of the few centers in the world to focus on cardiovascular genomic research. Dr. McCaffrey will lead a faculty of renowned experts, in the program.

"Leveraging the enormous resources of The George Washington University is a key part of how the Institute is approaching its mission to accelerate the pace of scientific discovery, reduce mortality and improve the quality of life of Americans with cardiovascular disease," said Dr. Richard J. Katz, who is the Director of the Cheney Cardiovascular Institute and Director of the Division of Cardiology. "An educational program like this one, on personalized medicine in cardiac care, holds the key to the next major advancements in cardiovascular care, which researchers, clinicians and policy makers must understand is one of the ways we're attacking cardiovascular disease and working to achieve our mission."

The symposium, titled "Personalized Medicine: The Genomic Revolution in Cardiac Care," is designated for 6 AMA PRA Category 1 Credits and will convene on October 25, 2007 at The George Washington University Hospital Auditorium, in Washington, DC. For more information about the symposium or to register, please visit

SOURCE The Cheney Cardiovascular Institute
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
2. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
3. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
4. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
5. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
6. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
9. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
10. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
11. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...sults from chronically infected Hepatitis C,patien...ned earlier in 2008, - Study is the first to sho... antiviral effect of therapeutic Hepatitis C vacci... move into a second generation, vaccine formulate... TLR activation, VI...
(Date:9/3/2008)...NEVA, Sept. 3 /- Artelis SA and,Selex... monoclonal antibody,production with the achieveme...ter. This record level was accomplished by applyin...erformance stable Selexis CHO,production cell line...at,Selexis SA using their proprietary Selexis Gene...
(Date:9/3/2008)...Multaq(R) (dronedarone) decreased the risk of,stro...trial flutter already adequately trea... Sept. 3 /- The results of ...udy were presented today at,the clinical trial upd...congress 2008, in Munich, Germany. Previous result...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 1Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 2Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 1Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 2Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 1Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 1HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 3
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...tem reserachers have identified a key receptor tha...e treatment of acute respiratory distress syndrome... a life-threatening condition. The receptor is s...ht, smell and taste (G-protein coupled receptors) ...
...doss urged the Prime Minister Mr. Man Mohan Singh ... smoking in the films and television. // With the ...ing failing to reach consensus on modalities for i...ss, the minister approached Prime Minister Manmoha...
...rchers might be able to isolates molecule that wou...ory.// The revolutionary study has been done indep...Children's Hospital Boston and they have identifie... how neurons change as a result of individual expe...
...he Bihar government on Wednesday for neglecting th...hief Minister of Bihar Mr. Nitish Kumar gave the n...which was carried out with immediate effect. Last...issed three medical officers and initiated departm...
Other Medicine News:
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts.
Velocity works cooperatively with LabSofts LabNet LIS, allowing the convenience of 24-hour access to information from satellite lab locations, hospitals, physician offices and even homes.
...eld (130" x 85") allows the surgeon to view the pa...hile remaining in the sterile field. , ,Electroca...ling cords while maintaining longer cord length st...large particle screen accommodates the larger inci...
The Bohn™ Extremity Drape is economically sound - this single extremity drape replaces two large antimicrobial impregnated "Vi-Drapes" ...the traditional "shower curtain"...and your current "ex
Medicine Products: